# Interius BioTherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/interius-biotherapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.interiusbio.com
- Total disclosed funding: $44M
- Latest round: Series A (May 14, 2021)
- Investors on record: 15

## About

Based in Pennsylvania, US, and founded in 2019, Interius BioTherapeutics, Inc. develops immunotherapies for cancer. The company was co-founded by Bruce A. Peacock and Saar Gill. In May 2021, the company raised its latest Series A funding co-led by Fairmount Funds Management and Cormorant Asset Management.

The company is developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities. The company's programs are focused on treating hematologic malignancies that generate chimeric antigen receptor (CAR) T cells directly in vivo.

The company plans to further expand its development efforts.

## Funding rounds

- Series A, May 14, 2021, $44M — Bain Capital, OUP (Osage University Partners), Longwood Fund, Pfizer Venture Investments, RA Capital Management, Cormorant Asset Management, Penn Medicine, Knollwood Investment Advisory, Fairmount Funds Management, Agent Capital, Quan Capital, Logos Capital, BrightEdge Ventures, Mark Foundation for Cancer Research, Tellus BioVentures

## Investors

- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Penn Medicine — Series A
- Knollwood Investment Advisory — Series A
- Fairmount Funds Management — Series A
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series A
- Mark Foundation for Cancer Research — Series A
- Tellus BioVentures (https://capitalatlas.ai/funds/tellus-bioventures) — Series A